Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (173)	12/4/2000 5:00:47 PM
From: nigel bates	Respond to of 539

TOKYO and SYDNEY, Australia, Dec. 4 /PRNewswire/ -- Proteome Systems Limited and Shimadzu Corporation today announced an extension of their strategic alliance through establishment of two world-class proteomics facilities in Sydney, Australia, and Boston, the USA, on December 4, 2000. This is the first result of their strategic alliance in proteomics that started in January, 2000. The core of the facilities will be advanced sample preparation technologies and Chemical Printers (jointly developed by Proteome Systems and Shimadzu) interfaced with AXIMA MALDI-TOF mass spectrometers. The AXIMA is manufactured by Kratos Analytical Limited, a wholly-owned subsidiary of Shimadzu, in Manchester, the United Kingdom. Furthermore, Shimadzu intends to implement the proteomics platform within its Kyoto facilities in 2001. The facility will also have a genomics program using the world's fastest capillary DNA sequencer RISA developed by Shimadzu. The combination of high level genomics and proteomics technologies will enable new insights into complex biological problems. As part of the collaboration, Shimadzu is combining its manufacturing technique with PSL's technology to develop new proteomics tools. PSL and Shimadzu are jointly developing new systems for high through-put analysis of proteins, which are intended to decrease manual handling. The first system will be launched around August, 2001. Other emerging proteomics instrumentation is being considered. For example, PSL's leading-edge technology and expertise for Glycosite analysis will be incorporated into the proteomics tools that Shimadzu is now developing by using its proven manufacturing technique of the instruments such as liquid chromatography, mass spectrometry and ultra-violet spectrophotometry. The goal is to develop an integrated platform of instruments for high level protein and glycoprotein characterization. To strengthen their alliance, PSL and Shimadzu are giving positive consideration to extending their cooperation to other fields of biotechnology. The 125 year old Japanese firm Shimadzu is a leading manufacturer of scientific instruments, with particular skills in the manufacture and marketing of analytical instruments, medical instruments and mass spectrometry through ownership of Kratos Analytical. Recently Shimadzu announced the release of its high throughput DNA sequencer to establish its presence in the field of genomics. Proteome Systems, with over 60 employees in Sydney and Boston, is one of a small group of companies globally with the capacity to conduct large-scale proteomics. Proteome Systems is a leading innovator in the development of high throughput proteomics platforms with its technology partners. It is also pioneering bioinformatic aspects of proteomics. * For further information please contact: * Mr. S. Hattori, * Executive Director, Shimadzu Corporation, Tokyo * Ph: 81 3 3219 5515 * Fax: 81 3 3219 5676 * Email: hattoris@shimadzu.co.jp * Dr. Keith Williams, * Chief Executive Officer * Proteome Systems Ltd, Sydney * Ph: 61 2 9889 1830 * Fax: 61 2 9889 1805 * Email: keith.williams@proteomesystems.com * Web: www.proteomesystems.com